Patents by Inventor Jeffrey J. Seilhamer

Jeffrey J. Seilhamer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6066488
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new cathepsin C homolog (RCP) expressed in THP-1 cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode RCP, expression vectors for the production of purified RCP, antibodies capable of binding specifically to RCP, hybridization probes or oligonucleotides for the detection of RCP-encoding nucleotide sequences, genetically engineered host cells for the expression of RCP, diagnostic tests for activation of monocyte/macrophages based on RCP-encoding nucleic acid molecules, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: May 23, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Roger Coleman, Scott Michael Braxton, Jeffrey J. Seilhamer
  • Patent number: 6060239
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel cellubrevins (cb). The present invention also provides for antisense molecules to the nucleotide sequences which encode cbs, expression vectors for the production of purified CBs, antibodies capable of binding specifically to CBs, hybridization probes or oligonucleotides for the detecting the induction of CB encoding nucleotide sequences, genetically engineered host cells for the expression of CBs, diagnostic tests for activated, inflamed or diseased cells and/or tissues based on CB-encoding nucleic acid molecules and antibodies capable of binding specifically to CBs.
    Type: Grant
    Filed: March 22, 1996
    Date of Patent: May 9, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Susan G. Stuart, Phillip R. Hawkins, Jeffrey J. Seilhamer, Lynn E. Murry
  • Patent number: 6033848
    Abstract: The present invention provides a polynucleotide (icel) which identifies and encodes a human ice homolog (ICEL) expressed in lung cells and tissues. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified ICEL peptide, antibodies capable of binding to ICEL, inhibitors which bind to ICEL and pharmaceutical compositions based on ICEL specific antibodies or inhibitors. The invention specifically provides for diagnostic assays which identify a disorder or disease with altered icel expression which allows identification and monitoring of hospital patients. These assays utilize icel encoding or controlling nucleic acid sequences, fragments or oligomers thereof, or antibodies specific for the peptide.
    Type: Grant
    Filed: August 1, 1995
    Date of Patent: March 7, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Scott Michael Braxton, Dinh Diep, Jeffrey J. Seilhamer
  • Patent number: 6025138
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode the hyaluronan receptor (hr) from human umbilical vein endothelial cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode hr, expression vectors for the production of purified HR, antibodies capable of binding specifically to HR, hybridization probes or oligonucleotides for detecting the upregulation of HR encoding nucleotide sequences, genetically engineered host cells for the expression of HR, diagnostic tests for activated, angiogenic, inflamed or metastatic cells and/or tissues based on HR-encoding nucleic acid molecules and antibodies capable of binding specifically to the receptor.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: February 15, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Craig G. Wilde, Jeffrey J. Seilhamer
  • Patent number: 6023659
    Abstract: Disclosed is a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. The hierarchies allow searches for sequences based upon a protein's biological function or molecular function. Also disclosed is a mechanism for automatically grouping new sequences into protein function hierarchies. This mechanism uses descriptive information obtained from "external hits" which are matches of stored sequences against gene sequences stored in an external database such as GenBank. The descriptive information provided with the external database is evaluated according to a specific algorithm and used to automatically group the external hits (or the sequences associated with the hits) in the categories.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: February 8, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jeffrey J. Seilhamer, Ingrid E. Akerblom, Christina M. Altus, Tod M. Klingler, Frank Russo, Janice Au-Young, Jennifer L. Hillman, Timothy J. Maslyn
  • Patent number: 5998165
    Abstract: The present invention provides polynucleotides and related reagents which are associated with pancreatic and other cancers. These polynucleotides are designated PANC1A.
    Type: Grant
    Filed: March 15, 1996
    Date of Patent: December 7, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Richard D. Goold, Ingrid E. Akerblom, Jeffrey J. Seilhamer, Roger Coleman
  • Patent number: 5972677
    Abstract: Novel mammalian phospholipase (PLA.sub.2) nucleotide sequences and low molecular weight (about 14KD) amino acid sequences encoded thereby are disclosed. More particularly, a cloned human HPLA.sub.2 cDNA expressing HPLA.sub.2 -10 and its cloned rat RPLA.sub.2 cDNA counterpart, expressing RPLA.sub.2 -10, which are characterized as PLA.sub.2 Type IV, are disclosed. A second type of PLA.sub.2 cDNA, characterized as PLA.sub.2 Type III and exemplified by a rat PLA.sub.2 cDNA encoding RPLA.sub.2 -8 and a partial human PLA.sub.2 nucleotide sequence encoding HPLA.sub.2 -8, is disclosed. Expression of the cDNAs encode the two new types of PLA.sub.2 enzymes which have phospholipase activity. The novel PLA.sub.2 s do not include disulfide bridges between cysteine amino acids 11 and 77 or elapid loops. However, the novel PLA.sub.2 s may include amino acid COOH-terminal extensions which can vary in length. Seventeen of the eighteen absolutely conserved amino acids in all active 14KD PLA.sub.
    Type: Grant
    Filed: July 7, 1997
    Date of Patent: October 26, 1999
    Assignees: J. Tischfield, Incyte Pharmaceuticals, Inc.
    Inventors: Jay A. Tischfield, Jeffrey J. Seilhamer
  • Patent number: 5945506
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (FSEC) from human fetal spleen cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode FSEC, expression vectors for the production of purified FSEC, antibodies capable of binding specifically to FSEC, hybridization probes or oligonucleotides for the detection of FSEC-encoding nucleotide sequences, genetically engineered host cells for the expression of FSEC, diagnostic tests for chemokine activation based on FSEC-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 31, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Roger Coleman, Craig G. Wilde, Jeffrey J. Seilhamer
  • Patent number: 5936068
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (ECs) from liver and pituitary gland tissues. The present invention also provides for antisense molecules to the nucleotide sequences which encode ECs, expression vectors for the production of purified ECs, antibodies capable of binding specifically to ECs, hybridization probes or oligonucleotides for the detection of EC-encoding nucleotide sequences, genetically engineered host cells for the expression of ECs, diagnostic tests for inflammation or disease based on on EC-encoding nucleic acid molecules or antibodies capable of binding specifically to ECs, pharmaceutical compositions to treat inflammation or disease based on EC-encoding nucleic acid molecules or antibodies capable of binding specifically to ECs.
    Type: Grant
    Filed: February 10, 1997
    Date of Patent: August 10, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Craig G. Wilde, Phillip R. Hawkins, Olga Bandman, Jeffrey J. Seilhamer
  • Patent number: 5932423
    Abstract: The invention provides human cyclic nucleotide phosphodiesterases (PDE8) and polynucleotides which identify and encode PDE8. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of PDE8.
    Type: Grant
    Filed: November 19, 1997
    Date of Patent: August 3, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Benjamin G. Cocks, Roger Coleman, Jeffrey J. Seilhamer, Douglas A. Fisher
  • Patent number: 5912130
    Abstract: The present invention provides a nucleic acid sequence which identifies and encodes a G protein gamma subunit (gpg) which was isolated from human pituitary gland. The invention provides for genetically engineered expression vectors and host cells comprising nucleic acid sequence encoding GPG and for gpg antisense molecules. The invention also provides for purified GPG; antibodies, antagonists and inhibitors which specifically bind GPG; and pharmaceutical compositions and methods of treatment based on GPG antagonists and inhibitors. The invention provides for diagnostic assays which utilize diagnostic compositions comprising nucleic acid sequences, or complements thereof, encoding GPG, purified GPG to be used as a positive control, and antibodies which specifically bind to GPG.
    Type: Grant
    Filed: July 7, 1998
    Date of Patent: June 15, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Susan G. Stuart, Lynn E. Murry, Karl J. Guegler, Jeffrey J. Seilhamer
  • Patent number: 5869633
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel thrombin receptor homolog (TRH) expressed in human liver. The present invention also provides for antisense molecules to the nucleotide sequences which encode TRH, diagnostic tests based on TRH encoding nucleic acid molecules, expression vectors for the production of purified TRH, antibodies capable of binding specifically to TRH, hybridization probes or oligonucleotides for the detection of TRH-encoding nucleotide sequences, genetically engineered host cells for the expression of TRH, and antagonists, antibodies and inhibitors with specific binding activity for the polypeptide TRH.
    Type: Grant
    Filed: August 14, 1997
    Date of Patent: February 9, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Roger Coleman, Janice Au-Young, Olga Bandman, Jeffrey J. Seilhamer
  • Patent number: 5866332
    Abstract: The present invention provides polynucleotide and amino acid sequences which encode and identify a novel human myeloid terminal differentiation response gene designated MYD118. The present invention also provides for myd118 antisense molecules. The invention further provides genetically engineered expression vectors and host cells for the production of purified MYD118 polypeptide; antibodies, antagonists and inhibitors of MYD118 polypeptide; and pharmaceutical compositions and methods of treatment based on polynucleotide sequences encoding MYD118 and MYD118 polypeptide. The invention specifically provides for use of the myd118 polynucleotide sequences as a diagnostic composition for the detection of myeloproliferative diseases and leukemias. The invention also relates to therapeutic methods and compositions based upon the nucleotide sequences for myd118. The invention further provides antibodies which specifically bind to MYD118.
    Type: Grant
    Filed: February 15, 1996
    Date of Patent: February 2, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Benjamin Graeme Cocks, Janice Au-Young, Jeffrey J. Seilhamer
  • Patent number: 5844084
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (ADEC) from inflamed adenoid tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode ADEC, expression vectors for the production of purified ADEC, antibodies capable of binding specifically to ADEC, hybridization probes or oligonucleotides for the detection of ADEC-encoding nucleotide sequences, genetically engineered host cells for the expression of ADEC, diagnostic tests for inflammation or disease based on ADEC-encoding nucleic acid molecules or antibodies capable of binding specifically to ADEC.
    Type: Grant
    Filed: May 23, 1997
    Date of Patent: December 1, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Karl J. Guegler, Phillip R. Hawkins, Craig G. Wilde, Jeffrey J. Seilhamer
  • Patent number: 5843719
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel cellubrevin (CB). The present invention also provides for antisense molecules to the nucleotide sequences which encode CB, expression vectors for the production of purified CB, antibodies capable of binding specifically to CB, hybridization probes or oligonucleotides for detecting the upregulation of CB encoding nucleotide sequences, genetically engineered host cells for the expression of CB, diagnostic tests for activated, inflamed or diseased cells and/or tissues based on CB-encoding nucleic acid molecules and antibodies capable of binding specifically to CB.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: December 1, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Susan G. Stuart, Phillip R. Hawkins, Jeffrey J. Seilhamer
  • Patent number: 5840484
    Abstract: A method and system for quantifying the relative abundance of gene transcripts in a biological sample. One embodiment of the method generates high-throughput sequence-specific analysis of multiple RNAs or their corresponding cDNAs (gene transcript imaging analysis). Another embodiment of the method produces a gene transcript imaging analysis by the use of high-throughput cDNA sequence analysis. In addition, the gene transcript imaging can be used to detect or diagnose a particular biological state, disease, or condition which is correlated to the relative abundance of gene transcripts in a given cell or population of cells. The invention provides a method for comparing the gene transcript image analysis from two or more different biological samples in order to distinguish between the two samples and identify one or more genes which are differentially expressed between the two samples.
    Type: Grant
    Filed: January 27, 1994
    Date of Patent: November 24, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jeffrey J. Seilhamer, Randal W. Scott
  • Patent number: 5840870
    Abstract: The present invention provides polynucleotide sequences designated PANC1A and PANC1B which are associated with a genomic sequence related to pancreatic cancer as well as other cancers. The present invention also provides for PANC1A and PANC1B antisense molecules. The invention further provides genetically engineered expression vectors and host cells for the production of purified PANC1A and PANC1B polypeptide; antibodies, antagonists and inhibitors of PANC1A and PANC1B polypeptide; and pharmaceutical compositions and methods of treatment based on the polypeptide, its antibodies, antagonists and inhibitors. The invention specifically provides for use of the polypeptide as a diagnostic composition for the detection of pancreatic cancer in individuals at risk for and subject to pancreatic cancer. The invention also relates to therapeutic methods and compositions based upon the nucleotide sequences for PANC1A and PANC1B.
    Type: Grant
    Filed: December 29, 1995
    Date of Patent: November 24, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Richard D. Goold, Ingrid E. Akerblom, Jeffrey J. Seilhamer
  • Patent number: 5798246
    Abstract: The present invention relates to a heretofore uncharacterized family of cyclic nucleotide phosphodiesterases (CN PCD8) and provides specific polynucleotide and amino acid sequences which encode and identify CN PDE8 family members designated herein as CN PDE8A and CN PDE8B. The present invention also relates to the use of proteins, peptides and organic molecules capable of modulating CN PDE8 activity to inhibit or enhance phosphodiesterase activity associated with disease. The present invention further relates to the use of CN PDE8 and genetically engineered host cells that express CN PDE8 to evaluate and screen for substances and compounds that modulate cyclic nucleotide phosphodiesterase activity. The present invention also provides for cn pde8 antisense molecules. The invention provides genetically engineered expression vectors and host cells for the production of purified CN PDE8 polypeptide.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: August 25, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Benjamin Graeme Cocks, Roger Coleman, Jeffrey J. Seilhamer
  • Patent number: 5783418
    Abstract: The present invention provides a nucleic acid sequence which identifies and encodes a G protein gamma subunit (gpg) which was isolated from human pituitary gland. The invention provides for genetically engineered expression vectors and host cells comprising nucleic acid sequence encoding GPG. The invention also provides for purified GPG.
    Type: Grant
    Filed: February 27, 1996
    Date of Patent: July 21, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Susan G. Stuart, Lynn E. Murry, Karl J. Guegler, Jeffrey J. Seilhamer
  • Patent number: 5783669
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode the hyaluronan receptor (hr) from human umbilical vein endothelial cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode hr, expression vectors for the production of purified HR, antibodies capable of binding specifically to HR, hybridization probes or oligonucleotides for detecting the upregulation of HR encoding nucleotide sequences, genetically engineered host cells for the expression of HR, diagnostic tests for activated, angiogenic, inflamed or metastatic cells and/or tissues based on HR-encoding nucleic acid molecules and antibodies capable of binding specifically to the receptor.
    Type: Grant
    Filed: August 20, 1996
    Date of Patent: July 21, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Craig G. Wilde, Jeffrey J. Seilhamer